Frontier Science Center for Synthetic Biology, Key Laboratory of Systems Bioengineering (MOE), Collaborative Innovation Centre of Chemical Science and Engineering (Tianjin), and School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, P. R. China.
Yangzhou Lianao Biopharmaceutical Co. Ltd. and Yangzhou Aurisco Pharmaceutical Co. Ltd., Wanmei Road No. 5, Hanjiang Economic Development Zone, Yangzhou City, Jiangsu Province 225100, P. R. China.
ACS Synth Biol. 2020 Jun 19;9(6):1385-1394. doi: 10.1021/acssynbio.0c00062. Epub 2020 May 27.
The production of the aglycosylated immunoglobulin G (IgG) in has received wide interest for its analytical and therapeutic applications. To enhance the production titer of IgG, we first used synthetic sRNAs to perform a systematical analysis of the gene expression in the translational level in the glycolytic pathway (module 1) and the tricarboxylic acid (TCA) cycle (module 2) to reveal the critical genes for the efficient IgG production. Second, to provide sufficient amino acid precursors for the protein biosynthesis, amino acid biosynthesis pathways (module 3) were enhanced to facilitate the IgG production. Upon integrated engineering of these genes in the three modules (module 1, ; module 2, and ; module 3, ) and optimization of fermentation conditions, the recombinant enabled a titer of the full-assembled IgG of 4.5 ± 0.6 mg/L in flask cultures and 184 ± 9.2 mg/L in the 5 L high cell density fed-batch fermenter, which is, as far as we know, the highest reported titer of IgG production in recombinant .
在分析和治疗应用方面,无糖基化免疫球蛋白 G(IgG)的生产引起了广泛关注。为了提高 IgG 的产量,我们首先使用合成的小 RNA 对糖酵解途径(模块 1)和三羧酸(TCA)循环(模块 2)中翻译水平的基因表达进行了系统分析,以揭示对高效 IgG 生产至关重要的基因。其次,为了给蛋白质生物合成提供足够的氨基酸前体,我们增强了氨基酸生物合成途径(模块 3)以促进 IgG 的生产。对这三个模块中的这些基因(模块 1,;模块 2,和;模块 3,)进行综合工程改造,并优化发酵条件后,重组 使完整组装的 IgG 的产量达到 4.5±0.6mg/L 的摇瓶培养和 184±9.2mg/L 的 5L 高细胞密度分批补料发酵罐,据我们所知,这是重组 中 IgG 产量的最高报道。